Undisclosed NLRP3 inhibitor / Halia Therap - LARVOL DELTA

Ofirnoflast: A First-in-Class NEK7-Targeted Inhibitor of the NLRP3 Inflammasome. (PubMed, J Drug Target) - "In a DSS-induced colitis model, treatment significantly reduces cytokine levels and improves clinical and histopathological outcomes. These data identify NEK7 as a novel, druggable target in NLRP3 inflammasome signaling and support ofirnoflast's potential as a differentiated therapeutic agent for certain chronic inflammatory diseases."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Targeted Protein Degradation • IL1B • NLRP3

Halia Therapeutics and Biolexis Therapeutics' Partnership Successfully Identifies Novel Clinical Candidate Targeting NLRP3-Driven Neuroinflammation (PRNewswire) - "Halia Therapeutics...and Biolexis Therapeutics...announced an ongoing collaboration that successfully identified a novel brain-penetrant small molecule candidate targeting NLRP3-driven neuroinflammation by leveraging Biolexis' MolecuLern AI-enabled approach. This milestone represents a significant advancement in developing treatments for neuroinflammatory disorders, including Parkinson's disease and other neurodegenerative conditions."

New molecule • CNS Disorders • Parkinson's Disease

Characterization of the NLRP3 Inflammasome Inhibitor HT-6184 in the Complete Freund's Adjuvant (CFA)-Induced Pain Model (PAINWeek 2023) - "This study highlights the potential of HT-6184 as an effective analgesic for treating inflammatory pain. HT-6184 demonstrated dose-dependent effects in reducing thermal hyperalgesia and mechanical allodynia in a pain model induced by CFA. Particularly, the 30 mpk doses of HT-6184 consistently improved paw withdrawal latency and threshold at all time points except 1 hour."

Clinical • CNS Disorders • Migraine • Neuralgia • Pain • IL18 • IL1B • NLRP3